Genix Pharmaceuticals Corporation prepares to file Abbreviated New Drug Submissions (ANDS) for its first ten Ophthalmic Drugs with Health Canada
Genix Introduces Paul Chow to the Board of Directors Vancouver,…
Genix Pharmaceuticals Corporation Announces Appointment of New Chief Financial Officer
Vancouver, British Columbia, December 15th, 2020 — Genix Pharmaceuticals Corporation…
Genix Pharmaceuticals Corporation Announces AGM Results and Welcomes New Director
Vancouver, British Columbia, September 22, 2020 — Genix Pharmaceuticals Corporation (TSX-V: GENX) (“GENIX” or…
Genix Pharmaceuticals Corporation Announces Closing of Second Tranche Financing and closing of acquisition of rights to Nutraceutical Products Sucanon® and Renochlor®
VANCOUVER, BRITISH COLUMBIA, August 6, 2020 — Genix Pharmaceuticals Corporation…
Genix Pharmaceuticals Corporation Announces Closing of Initial Tranche of Over Subscribed Non-Brokered Private Placement
VANCOUVER, BRITISH COLUMBIA, July 17, 2020 — Genix Pharmaceuticals Corporation (TSX-V: GENX)…
Genix Pharmaceuticals Corporation Announces the Extension of Payment Terms for the Acquisitions of Rights to Renochlor®, Sucanon® and Flu-x™
VANCOUVER, BRITISH COLUMBIA, June 30, 2020 — Genix Pharmaceuticals Corporation (TSX-V: GENX) (“GENIX”…